annotations = {'HIV-HIV-2017-Bekker-HVTN100.pdf': '252',
               'HIV-HIV-2016-Kurth-High-yield HIV testing, facilitated linkage to care.pdf': '1200',
               'HIV-HIV-2018-Lockman-Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy.pdf': '639',
               'HIV-HIV-2018-Long-acting Cabotegravir Plus Long-acting Rilpivirine.pdf': '1020',
               'HIV-HIV-2017-Abrams-IMPAACT P1101.pdf': '36 - 108',
               'HIV-HIV-2017-Corey-HVTN703-HPTN081.pdf': '1900',
               'HIV-HIV-2017-Corey-HVTN704-HPTN085.pdf': '2700',
               'HIV-HIV-2016-Garrett-HVTN108.pdf': '334',
               'HIV-HIV-2018-GSK1265744.pdf': '60',
               'HIV-HIV-2018-Labhardt-CASCADE.pdf': '260',
               'HIV-HIV-2016-Weinberg-NICHP1091.pdf': '345 mother-infant pairs',
               'HIV-HIV-2019-Venter-ADVANCE.pdf': '1050',
               'HIV-HIV-2017-Evolocumab-AMG145.pdf': '450',
               'HIV-HIV-2018-Havlir-SEARCH.pdf': '2700 residents per community',
               'HIV-HIV-2018-IMPAACT-P1112.pdf': '79 mother-infant pairs',
               'HIV-HIV-2016_Tebas-A5354.pdf': '196',
               'HIV-HIV-2016-HVTN114.pdf': '100',
               'HIV-HIV-2016-Laufer-Trimethoprim-Sulfamethoxazole-Chloroquine.pdf': '1500',
               'TB-TB-2020-John-Stewart-iTIPS.pdf': '300',
               'TB-TB-2018-DAR-PIA.pdf': '650',
               'TB-TB-2018-Churchyard-Bedaquiline-Delamanid.pdf': '84',
               'TB-TB-2018-M-P-A.pdf': '240',
               'HIV-HIV-2016-Ayles-A Study of the HIV prevention Trials Network.pdf': '2500',
               'TB-TB-2019-T-A-b.pdf': '450',
               'NTD-Filariasis-2019-Weil-DOLF IDA Papua New Guinea.pdf': '3000 participants per arm',
               'NUT-A-2019-M-T.pdf': '3954',
               'EDD-rotavirus-2017-Isanaka-ROSE.pdf': '7770',
               'NTD-Y-2019-M-Y.pdf': '1000',
               'NTD-Chagas-2015-Morillo-BENEFIT.pdf': '3000',
               'MAT-V-2018-R-M.pdf': '1300',
               "POL-P-2018-O-A-L.pdf": '570',
               'MAT-Hypothermia-2018-Hansen-Electricity-free Infant Warmer.pdf': '102',
               'EDD-T-2019-S-T.pdf': '20000',
               'NTD-Hookwork-2018-Keiser-Efficacy and safety of a single.pdf': '180',
               'TB-TB-2018-Piazza-A Phase 1b, Randomized, Double-blind.pdf': '66',
               'MAL-Malaria-2019-Llanos-Cuentas-Tafenoquine vs. Primaquine to.pdf': '300',
               'MAL-M-2019-A-S.pdf': '2279',
               'NTD-E-2017-A-A.pdf': '250',
               'MAL-Malaria-2019-Tinto-Extension to study MALARIA-055 PRI.pdf': '3000 to 4000',
               'NUT-NUT-2019-A-I.pdf': '410',
               # 'HIV-HIV-2018-M-A.pdf': None, # image PDF
               'HIV-HIV-2017-L-I.pdf': '440',
               'TB-TB-2019-M-A.pdf': '3120',
               'VAC-G-2016-VAC-G-2016-V.pdf': '270',
               'HIV-HIV-2016-N-S.pdf': '1950',
               'VAC-Shigellosis-2019-Raqib-Shigella WRSS1 Vaccine trial in Bangladesh.pdf': '64',
               'TB-TB-2015-D-A.pdf': '2076',
               'POL-P-2016-G-T.pdf': '750',
               'TB-TB-2019-Suliman-A Phase I_IIa Double-Blind.pdf': '98',
               'MAT-Anemia-2015-Etheredge-Prenatal Iron Supplements Safety and.pdf': '1500',
               'HIV-HIV-2016-R-E.pdf': '1000-1500',
               'HIV-HIV-2019-H-S.pdf': '2700 per community', # 150395 according to CT.gov
               'NTD-Filariasis-2019-Weil-DOLF IDA Haiti.pdf': '3000 participants in each arm',
               # 'MAT-MAT-2018-G-F.pdf': None, # not mentioned
               'EDD-R-2017-G-V.pdf': "450",
               'MAT-HIV-2016-Fowler-PROMISE.pdf': "3400",
               'TB-TB-2018-H-A.pdf': "990",
               'NUT-S-2018-R-S.pdf': "600", # per arm
               'VAC-Tdap-2019-Sancovski-A Post-marketing, Observational, Retrospective.pdf': "2400", # 1200 in each cohort
               'NTD-t-2017-M-E.pdf': '510',
               'MAL-M-2018-D-C.pdf': '300',
               'NTD-D-2017-S-P.pdf': '1600',
               'TB-TB-2019-Dawson-A Phase 2 Open‚ÄêLabel Partially .pdf': '240',
               'MAL-MAL-2018-Dorsey-PROMOTE Birth Cohort 1.pdf': '400',
               'PNE-P-2019-C-P.pdf': '1125',
               'HIV-HIV-2019-K-C.pdf': '6400',
               'PNE-Pneumonia-2019-Alexander-LEAP2.pdf': '738',
               'MAT-Cervical Disease-2019-Greene-LEEP.pdf': '400', # 200 in each arm
               'MAL-Malaria-2019-Foy-RIMDAMAL.pdf': '552',
               'TB-TB-2019-N-S.pdf': '400', # 2 arms
               'NUT-Stunting-2019-Humphrey-SHINE.pdf': '4800', # 4 arms
               'PNE-Pneumonia-2018-Keenan-Mortality Reduction After Oral Azithromycin.pdf':'226222', # 2 arms,  62628+69472+94122
               'EDD-Cholera-2016-Qadri-Shanchol.pdf': '190,229', # 2 arms: we need at least 95,115 individuals in an arm of the study i.e., a total of 190,229 population will be required to conduct the trial.
               'VAC-Ecoli-2019-Qadri-ETVAX.pdf': '45', # 45 adults then part B has 150 toddlers
               'MAL-Malaria-2016-Valencia-Phase 1 and 2a Clinical.pdf': '28',
               'NTD-Filariasis-2019-Weil-DOLF IDA Indonesia.pdf': '4000', # 2 arms: The sample size of 2000 participants in each arm
               'VAC-M-2015-L-W.pdf': '2000'}
